Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Small Cell Lung Cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
1430 results:

  • 1. Targeted therapeutic options in early and metastatic NSCLC-overview.
    Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
    Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-lung01): primary results of the her2-overexpressing cohorts from a single-arm, phase 2 trial.
    Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
    Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Discovery of Novel 5,6-Dihydro-4
    Yang L; Li Y; Du Y; Guo Y; Guo Z; Liu B; Liu J; Liu Y; Niu H; Sun Y; Yan H; Yang Y; Yu S; Zhang Y; Zhang Y; Zheng K; Zheng N; Zhang X; Zhang Q; Hu L
    J Med Chem; 2024 Apr; 67(7):5662-5682. PubMed ID: 38518121
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
    Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
    Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
    Heist RS; Sands J; Bardia A; Shimizu T; Lisberg A; Krop I; Yamamoto N; Kogawa T; Al-Hashimi S; Fung SSM; Galor A; Pisetzky F; Basak P; Lau C; Meric-Bernstam F
    Cancer Treat Rev; 2024 Apr; 125():102720. PubMed ID: 38502995
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Advances in the treatment of anti-her-2 antibody drug conjugates in pan-tumor with low her-2 expression].
    Wei T; Yuan P
    Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):211-220. PubMed ID: 38494768
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. EGFR and erbb2 Exon 20 Insertion Mutations in Chinese Non-small cell lung cancer Patients: Pathological and Molecular Characterization, and First-Line Systemic Treatment Evaluation.
    Zhao R; Li J; Guo L; Xiang C; Chen S; Zhao J; Shao J; Zhu L; Ye M; Qin G; Chu T; Han Y
    Target Oncol; 2024 Mar; 19(2):277-288. PubMed ID: 38416376
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Synchronous double primary small cell lung cancer and invasive ductal breast carcinoma: a case report.
    Gan J; Liu M; Liu F; Wen J; Fu W; Jia J
    BMC Pulm Med; 2024 Feb; 24(1):93. PubMed ID: 38388422
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.
    Cardillo TM; Zalath MB; Arrojo R; Sharkey RM; Govindan SV; Chang CH; Goldenberg DM
    Oncotarget; 2024 Feb; 15():144-158. PubMed ID: 38386805
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. miRNA-449c-5p regulates the JAK-STAT pathway in inhibiting cell proliferation and invasion in human breast cancer cells by targeting erbb2.
    Li L; Zhang Y; Yang K; Liu W; Zhou Z; Xu Y
    Cancer Rep (Hoboken); 2024 Feb; 7(2):e1974. PubMed ID: 38351535
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Leucine Zipper Downregulated in cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-small cell lung cancer.
    Huang HN; Hung PF; Chen YP; Lee CH
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338651
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Deciphering the heterogeneity of neutrophil cells within circulation and the lung cancer microenvironment pre- and post-operation.
    Liu F; Liu X; Liu Y; Chen D; Liu X; Qin C; Song Y; Fang H; Wu D
    Cell Biol Toxicol; 2024 Feb; 40(1):11. PubMed ID: 38319415
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small cell lung cancer.
    Kanasaki H; Ozawa Y; Nakamura N; Nagasaki K; Matsuyama W; Akahori D; Niwa M; Ogasawara T; Sato J
    Anticancer Res; 2024 Feb; 44(2):723-730. PubMed ID: 38307579
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Efficacy of immunotherapy in her2-mutated non-small cell lung cancer: a single-arm meta-analysis.
    Zhang J; Han W; Guo J; Zhang C; Cao L; Peng L; Han X; Wang Z
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):42. PubMed ID: 38280966
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift.
    Tantawy MN; McIntyre JO; Yull F; Calcutt MW; Koktysh DS; Wilson AJ; Zu Z; Nyman J; Rhoades J; Peterson TE; Colvin D; McCawley LJ; Rook JM; Fingleton B; Crispens MA; Alvarez RD; Gore JC
    Cancer Med; 2024 Feb; 13(3):e6812. PubMed ID: 38239047
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update.
    Roskoski R
    Pharmacol Res; 2024 Feb; 200():107059. PubMed ID: 38216005
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Prognostic and predictive biomarkers in non-small cell lung carcinoma.
    Odintsov I; Sholl LM
    Pathology; 2024 Mar; 56(2):192-204. PubMed ID: 38199926
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Comprehensive Genomic Analysis of Patients With Non-small-cell lung cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
    Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ
    JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
    Liu X; Deng J; Zhang R; Xing J; Wu Y; Chen W; Liang B; Xing D; Xu J; Zhang M
    Front Immunol; 2023; 14():1335252. PubMed ID: 38162667
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Efficacy and safety of a pyrotinib-based regimen in non-small cell lung cancer patients harboring her2 alterations: A real-world retrospective study.
    Wang X; Wang J; Chu Y; Hao J
    J Cancer Res Ther; 2023 Dec; 19(6):1663-1668. PubMed ID: 38156935
    [TBL] [Abstract] [Full Text] [Related]  


    of 72.